US-based Boston Consulting Group (BCG) and Hippocratic AI have announced a global collaboration to advance the deployment of generative AI (genAI) healthcare agents in the biopharma and medtech industries.
The partnership aims to encourage responsible adoption of agentic AI, combining Hippocratic AI’s technology with BCG’s strategic and operational expertise.
Despite increasing digital investment, BCG’s benchmarks reveal that only a minority of biopharma and medtech companies achieve lasting value from AI. The collaboration seeks to address this gap by transitioning organisations from limited experimentation to enterprise-wide impact with genAI.
Hippocratic AI will provide its genAI healthcare agents, tailored for regulated clinical and life sciences applications.
Having supported more than 150 million clinical interactions, these agents assist with non-diagnostic, patient-facing activities such as adherence engagement, onboarding, post-market monitoring, and clinical trial support. Developed using the proprietary Polaris Constellation architecture, these agents provide reliable, safe and empathetic support intended to support human teams.
BCG contributes advisory and AI transformation expertise for C-level leaders, including its Health Care Commercial AI by BCG X solution. This offering is intended to help modernise commercial models, enhance omnichannel engagement, and realise measurable performance improvements.
BCG’s approach is informed by continued research from BCG X, which includes benchmark studies and global roundtables on AI adoption in life sciences.
BCG managing director and senior partner Ashkan Afkhami said: “This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI’s sophisticated AI agent platform, BCG’s strategy and governance expertise, and BCG X’s Health Care Commercial AI solution to help clients turn potential into measurable business value.”
Hippocratic AI founder and CEO Munjal Shah said: “Our collaboration with BCG is built on a shared commitment to improving patient outcomes.
“By combining BCG’s deep strategic and operational expertise with our safety-focused genAI healthcare agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world.”
In November 2025, Hippocratic AI secured $126m in a Series C funding round for the expansion of clinically safe genAI agents across healthcare.
